CollPlant Biotechnologies Ltd. reported its financial results for the three months ended March 31, 2025. The company experienced a significant increase in revenues, which rose to $2.055 million compared to $98,000 in the same period the previous year. Despite the increase in revenues, the company reported a net loss of $1.452 million, a notable improvement from the $4.195 million loss reported in the first quarter of 2024. The total operating loss for the quarter was $1.648 million, down from $4.329 million the year prior. This improvement in financial performance is reflected in the non-GAAP net loss, which decreased to $1.130 million from $3.954 million in the previous year. CollPlant's management emphasized that the non-GAAP financial measures provide meaningful supplemental information regarding the company's performance, excluding non-cash expenses related to share-based compensation and changes in operating lease accounts. No specific outlook or guidance for future periods was provided in the release.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.